{
  "documents": [
    {
      "id": "cluster_4_doc1",
      "content": "Silvervale Health Network reported a 28% increase in prior authorization requests for genetic testing during Q3 2023, particularly for BRCA mutation screening in patients under 45 following revised coverage guidelines under policy GH-2281. Three affiliated clinics accounted for 62% of these requests.",
      "metadata": {
        "format": "insurance_memo"
      }
    },
    {
      "id": "cluster_4_doc2",
      "content": "Patient #4548-ZT underwent BRCA1 testing at Clearwater Diagnostics on 08/14/2023 after presenting with early-onset breast cancer at age 42. The claim was processed under genetic counseling benefit code TC-45X with 80% coverage. Referring provider: Dr. Miriam Kellerman [ID#P8842].",
      "metadata": {
        "format": "claim_form"
      }
    },
    {
      "id": "cluster_4_doc3",
      "content": "Research bulletin from NE Metro Health District shows BRCA-positive patients under 45 required twice as many supplemental imaging studies compared to older cohorts. Data includes 37 cases from Silvervale Network providers between 2021-2023.",
      "metadata": {
        "format": "research_note"
      }
    },
    {
      "id": "cluster_4_doc4",
      "content": "Policy alert: GH-2281 revised genetic testing criteria effective 06/01/2023 now require documented family history + predictive risk score â‰¥7.5 for coverage. Shared via portal message #4452-8T to all Silvervale-affiliated providers.",
      "metadata": {
        "format": "policy_document"
      }
    },
    {
      "id": "cluster_4_doc5",
      "content": "Quality improvement report indicates Silvervale's Maplewood Clinic achieved 94% compliance with new genetic counseling documentation requirements, compared to 67% network-wide average. Reviewed 88 cases between 07-09/2023.",
      "metadata": {
        "format": "audit_report"
      }
    },
    {
      "id": "cluster_4_doc6",
      "content": "Email correspondence shows patient #4548-ZT required pre-authorization appeal for MRI breast screening following positive BRCA result. Case escalated to medical director on 09/05/2023 due to imaging frequency exceeding policy limits.",
      "metadata": {
        "format": "provider_report"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_4",
    "cluster_risk": "MEDIUM",
    "content_summary": "Genetic testing policy changes and patient journey through BRCA screening, authorization appeals, and associated research findings within Silvervale Health Network",
    "person": {
      "entities": [
        [
          "4548-ZT",
          "PATIENT_ID"
        ],
        [
          "42",
          "AGE"
        ],
        [
          "BRCA1",
          "MEDICAL_CONDITION"
        ],
        [
          "early-onset breast cancer",
          "MEDICAL_CONDITION"
        ],
        [
          "08/14/2023",
          "EVENT_DATE"
        ],
        [
          "TC-45X",
          "TREATMENT"
        ],
        [
          "MRI breast screening",
          "TREATMENT"
        ],
        [
          "09/05/2023",
          "EVENT_DATE"
        ],
        [
          "pre-authorization appeal",
          "EVENT"
        ],
        [
          "case escalated to medical director",
          "EVENT"
        ],
        [
          "positive BRCA result",
          "UNIQUE_FACT"
        ],
        [
          "imaging frequency exceeding policy limits",
          "UNIQUE_FACT"
        ]
      ]
    },
    "questions": [
      {
        "q": "Which genetic counseling benefit code and coverage percentage applied to patient 4548-ZT's BRCA1 testing?",
        "a": "Code TC-45X with 80% coverage",
        "sources": [
          "cluster_4_doc2"
        ],
        "type": "specific"
      },
      {
        "q": "What two documentation compliance rates were reported for Silvervale Network's new genetic testing requirements?",
        "a": "94% at Maplewood Clinic versus 67% network-wide",
        "sources": [
          "cluster_4_doc5"
        ],
        "type": "general"
      },
      {
        "q": "Which provider and testing facility handled patient 4548-ZT's BRCA evaluation that later required imaging appeal?",
        "a": "Dr. Miriam Kellerman at Clearwater Diagnostics",
        "sources": [
          "cluster_4_doc2",
          "cluster_4_doc6"
        ],
        "type": "specific"
      },
      {
        "q": "What policy revision and date drove increased genetic testing requests in Silvervale Network?",
        "a": "Policy GH-2281 with criteria changes effective 06/01/2023",
        "sources": [
          "cluster_4_doc1",
          "cluster_4_doc4"
        ],
        "type": "general"
      }
    ]
  }
}